Literature DB >> 16296788

Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.

Ingo Alberti1, Arnaud Grenier, Holger Kraus, Dario Norberto Carrara.   

Abstract

Transdermal gels are designed to deliver sustained drug amounts, resulting in systemically consistent levels. They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance. Advanced Transdermal Delivery (ATD) gel technology was developed in order to provide enhanced passive skin permeation of various active drugs for the treatment of many conditions, including hypogonadism, female sexual dysfunction, postmenopausal symptoms, overactive bladder and anxiety. The technology consists of a combination of solvent systems and permeation enhancers enabling systemic drug delivery, and is covered by many patents. Pharmaceutical development of formulations based on the technology allowed optimisation of physicochemical parameters (rheological profile, pH) as well as skin permeation properties (type and concentration of permeation enhancers, thermodynamic activity of the drug). This gel technology has demonstrated to be efficient for many drugs, as shown in the preclinical and clinical pharmacokinetic studies presented in this technology evaluation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296788     DOI: 10.1517/17425247.2.5.935

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  9 in total

Review 1.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

2.  A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder.

Authors:  Michael J Kennelly
Journal:  Rev Urol       Date:  2010

3.  [Testosterone replacement: application and surveillance].

Authors:  G Popken
Journal:  Urologe A       Date:  2010-01       Impact factor: 0.639

Review 4.  An update on the use of transdermal oxybutynin in the management of overactive bladder disorder.

Authors:  Joshua A Cohn; Elizabeth T Brown; W Stuart Reynolds; Melissa R Kaufman; Douglas F Milam; Roger R Dmochowski
Journal:  Ther Adv Urol       Date:  2016-01-19

Review 5.  [Andrological testosterone replacement therapy].

Authors:  U Paasch; H-J Glander; J-U Stolzenburg
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

Review 6.  The Potential of Pharmaceutical Hydrogels in the Formulation of Topical Administration Hormone Drugs.

Authors:  Aneta Ostróżka-Cieślik
Journal:  Polymers (Basel)       Date:  2022-08-14       Impact factor: 4.967

Review 7.  Transdermal oxybutynin in the treatment of overactive bladder.

Authors:  G Willy Davila
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

Review 8.  Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.

Authors:  Adrian Wagg
Journal:  Res Rep Urol       Date:  2012-11-27

Review 9.  Film-Forming Systems for Dermal Drug Delivery.

Authors:  Larissa Carine Pünnel; Dominique Jasmin Lunter
Journal:  Pharmaceutics       Date:  2021-06-23       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.